Characteristics of Previous Tuberculosis Treatment History in Patients with Treatment Failure and the Impact on Acquired Drug-Resistant Tuberculosis

Author:

Soedarsono Soedarsono12ORCID,Mertaniasih Ni Made34ORCID,Kusmiati Tutik14,Permatasari Ariani14,Ilahi Wiwik Kurnia5,Anggraeni Amelia Tantri5

Affiliation:

1. Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60131, Indonesia

2. Sub-Pulmonology Department of Internal Medicine, Faculty of Medicine, Hang Tuah University, Surabaya 60244, Indonesia

3. Department of Clinical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya 60131, Indonesia

4. Tuberculosis Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya 60131, Indonesia

5. Division of Pulmonary Medicine, Ibnu Sina General Hospital, Gresik 61121, Indonesia

Abstract

Tuberculosis (TB) treatment failure is a health burden, as the patient remains a source of infection and may lead to the development of multi-drug resistance (MDR). Information from cases of treatment failure that develop into MDR, which is related to a history of previous TB treatment, in accordance with the pharmacokinetic aspect, is one important thing to prevent TB treatment failure and to prevent drug resistance. This was an observational descriptive study in an acquired MDR-TB patient who had a prior history of treatment failure. A structured questionnaire was used to collect information. The questionnaire consisted of a focus on the use of TB drug formulas during the treatment period, as well as when and how to take them. This study included 171 acquired MDR-TB patients from treatment failure cases. An amount of 64 patients received the separated TB drug, and 107 patients received the fixed dose combination (FDC) TB drug. An amount of 21 (32.8%) patients receiving separated TB drug and six (5.6%) patients receiving FDC TB drug took their drug in divided doses. In addition, three (4.7%) patients receiving separated TB drug and eight (7.5%) patients receiving FDC TB drug took their drug with food. An amount of 132 out of 171 (77.2%) patients had a history of incorrect treatment that developed into MDR-TB. Education on how to take the correct medication, both the separate version and the FDC TB drug, according to the pharmacokinetic aspect, is important before starting TB treatment.

Funder

Universitas Airlangga

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Reference41 articles.

1. World Health Organization (WHO) (2022). Global Tuberculosis Report 2022, World Health Organization.

2. Drug-resistant tuberculosis and hiv infection: Current perspectives;Singh;HIV/AIDS—Res. Palliat. Care,2020

3. World Health Organization (WHO) (2022, December 05). Companion handbook. World Health Organization. Available online: http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf.

4. First Line Anti-Tuberculosis Drug Resistance Pattern in Multidrug-Resistant Pulmonary Tuberculosis Patients Correlate with Acid Fast Bacilli Microscopy Grading;Soedarsono;Indones. J. Trop. Infect. Dis.,2020

5. World Health Organization (2020). Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis, World Health Organization. CC BY-NC-SA 3.0 IGO.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3